SEC Comment Letter 0000000000-24-000719 to ADIAL PHARMACEUTICALS, INC. (ADIL)
ADIAL PHARMACEUTICALS, INC.
Date: Jan. 19, 2024 · CIK: 0001513525 · Accession: 0000000000-24-000719
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276496
Letter
United States securities and exchange commission logo January 19, 2024 Joseph Truluck Chief Financial Officer Adial Pharmaceuticals, Inc. 1180 Seminole Trail, Suite 495 Charlottesville, VA 22901 Re:Adial Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed January 12, 2024 File No. 333-276496 Dear Joseph Truluck: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Leslie Marlow, Esq.
Show Raw Text
United States securities and exchange commission logo
January 19, 2024
Joseph Truluck
Chief Financial Officer
Adial Pharmaceuticals, Inc.
1180 Seminole Trail, Suite 495
Charlottesville, VA 22901
Re:Adial Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed January 12, 2024
File No. 333-276496
Dear Joseph Truluck:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Leslie Marlow, Esq.